




Our Global Experience. Your Success.

*A clinical study wherein SIRO delivered more than 40% of the entire study data*



## Therapeutic Area - Ophthalmology

US-based MNC sponsor

### **Sponsor Requirement**

260 patients in a Phase III Trial

### **Indication**

Ophthalmology/Uveitis

### **Strategy**


Recruitment in 6 countries, Maximum patient load from India

### **Protocol Complexity**

Drug had to be inserted in to the eye through a catheter every fortnight

### **Study Background:**

- USFDA IND Submission
- Orphan Drug Indication



**Recruitment completed in 9 months**

**Approved by USFDA!!**

The data was accepted by the USFDA and the drug is currently being marketed